$MAPS
WM TECHNOLOGY, INC.

2019 Q3 Form 10-Q Financial Statement

#000114036119020475 Filed on November 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $133.6K
YoY Change
Operating Profit -$133.6K
YoY Change
Interest Expense $690.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $550.0K
YoY Change
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $553.1K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.000M
YoY Change
Cash & Equivalents $987.3K
Short-Term Investments
Other Short-Term Assets $300.0K
YoY Change
Inventory
Prepaid Expenses $312.1K
Receivables
Other Receivables
Total Short-Term Assets $1.299M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $250.7M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $250.7M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.299M
Total Long-Term Assets $250.7M
Total Assets $252.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $76.40K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $76.40K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $8.800M
YoY Change
Total Long-Term Liabilities $8.800M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $76.40K
Total Long-Term Liabilities $8.800M
Total Liabilities $8.826M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $548.1K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M
YoY Change
Total Liabilities & Shareholders Equity $252.0M
YoY Change

Cashflow Statement

Concept 2019 Q3
OPERATING ACTIVITIES
Net Income $553.1K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$360.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$250.0M
YoY Change
Cash From Investing Activities -$250.0M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 251.4M
YoY Change
NET CHANGE
Cash From Operating Activities -360.0K
Cash From Investing Activities -250.0M
Cash From Financing Activities 251.4M
Net Change In Cash 990.0K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$360.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Address Country
EntityAddressCountry
KY
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001779474
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Shell Company
EntityShellCompany
true
dei Entity Registrant Name
EntityRegistrantName
Silver Spike Acquisition Corp.
us-gaap Investment Income Interest
InvestmentIncomeInterest
620669
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76397
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4451128
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7000000
CY2019Q3 us-gaap Assets
Assets
251986158
CY2019Q3 us-gaap Assets Current
AssetsCurrent
1299415
CY2019Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
250686743
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
987278
CY2019Q3 us-gaap Cash
Cash
987278
CY2019Q3 us-gaap Cash
Cash
1774430
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
987278
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-weight: bold;">Concentration of credit risk</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</div></div>
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2019Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
66074
us-gaap Gain Loss On Investments
GainLossOnInvestments
66074
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
76397
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
312137
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
620669
CY2019Q3 us-gaap Liabilities
Liabilities
8826397
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
251986158
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
76397
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</div><div style="text-align: justify; margin-right: 18pt;"><br /></div><div style="text-align: justify;">Silver Spike Acquisition Corp. (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on June 7, 2019. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (&#8220;Business Combination&#8221;).</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses in the cannabis industry that are compliant with all applicable laws and regulations within the jurisdictions in which they are located or operate and, in particular, the Company will not invest in, or consummate a Business Combination with, a target business that the Company determines has been operating, or whose business plan is to operate, in violation of U.S. federal laws, including the U.S. Controlled Substances Act. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</div><div><br /></div><div style="text-align: justify;">As of September 30, 2019, the Company had not commenced any operations. All activity for the period from June 7, 2019 (inception) through September 30, 2019 relates to the Company's formation, the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.</div><div><br /></div><div style="text-align: justify;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August 7, 2019. On August 12, 2019, the Company consummated the Initial Public Offering of 25,000,000 units (the &#8220;Units&#8221; and, with respect to the Class A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;) at $10.00 per unit, generating gross proceeds of $250,000,000, which is described in Note 3.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 7,000,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $1.00 per Private Placement Warrant in a private placement to Silver Spike Sponsor, LLC (the &#8220;Sponsor&#8221;), generating gross proceeds of $7,000,000, which is described in Note 4.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">Transaction costs amounted to $14,413,362, consisting of $5,000,000 of underwriting fees, $8,750,000 of deferred underwriting fees and $663,362 of other offering costs. In addition, $1,774,430 of cash was held outside of the Trust Account upon closing of the Initial Public Offering and was available for working capital purposes.</div><div><br /></div><div style="text-align: justify;">Following the closing of the Initial Public Offering on August 12, 2019, an amount of $250,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of the Business Combination and (ii) the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below.</div><div><br /></div><div style="text-align: justify;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Nasdaq rules provide that the Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.</div><div><br /></div><div style="text-align: justify;">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.00 per share) as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants.</div><div><br /></div><div style="text-align: justify;">The Company will proceed with a Business Combination only if the Company has net tangible assets, after payment of the deferred underwriting commission, of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination and to waive its redemption rights with respect to any such shares in connection with a shareholder vote to approve a Business Combination or seek to sell any shares to the Company in a tender offer in connection with a Business Combination. Additionally, subject to the immediately succeeding paragraph, each public shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to 15% or more of the Public Shares without the Company&#8217;s prior written consent.</div><div><br /></div><div style="text-align: justify;">The Sponsor has agreed (a) to waive its redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination (and not seek to sell its shares to the Company in any tender offer the Company undertakes in connection with its initial Business Combination) and (b) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company&#8217;s obligation to redeem 100% of the Public Shares if the Company does not complete a Business Combination within 18 months from the closing of the Public Offering or (ii) with respect to any other provision relating to shareholders&#8217; rights or pre-initial business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment and (c) that the Founder Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">The Company will have until February 12, 2021 (the &#8220;Combination Period&#8221;) to consummate a Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company&#8217;s board of directors, dissolve and liquidate, subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</div><div><br /></div><div style="text-align: justify;">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-374360
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-250000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
251361638
us-gaap Net Income Loss
NetIncomeLoss
548123
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
553123
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99283
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104283
us-gaap Operating Expenses
OperatingExpenses
138620
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
133620
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-133620
us-gaap Operating Income Loss
OperatingIncomeLoss
-138620
CY2019Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
686743
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
686743
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
638362
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
250000000
CY2019Q3 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
250000000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
312137
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
245000000
CY2019Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
250000000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7000000
CY2019Q3 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7000000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
237470
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
237470
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
548123
CY2019Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2019Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5000001
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
0
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20000
CY2019Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
652406
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
652406
CY2019Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
23750733
CY2019Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
238159760
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-weight: bold;">Use of estimates</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period.</div><div style="text-align: justify; text-indent: 18pt;"><br /></div><div style="text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates.</div></div>
CY2019Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6910082
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6792210
sspk Underwriting Discount Fee Deferred
UnderwritingDiscountFeeDeferred
0.35
sspk Underwriting Fees Deferred
UnderwritingFeesDeferred
8750000
sspk Underwriting Discount Fee
UnderwritingDiscountFee
0.20
sspk Underwriting Fees
UnderwritingFees
5000000
CY2019Q3 sspk Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
8750000
CY2019Q3 sspk Forfeiture Of Shares Value
ForfeitureOfSharesValue
0
CY2019Q3 sspk Reclassifications Of Permanent To Temporary Equity Value
ReclassificationsOfPermanentToTemporaryEquityValue
238159760
CY2019Q3 sspk Shares Issued In Initial Public Offering During Period Value New Issues
SharesIssuedInInitialPublicOfferingDuringPeriodValueNewIssues
235586638
sspk Offering Costs Paid Directly From Proceeds From Issuance Of Shares
OfferingCostsPaidDirectlyFromProceedsFromIssuanceOfShares
25000
sspk Increase Decrease In Value Of Shares Subject To Possible Redemption
IncreaseDecreaseInValueOfSharesSubjectToPossibleRedemption
553130
sspk Initial Classification Of Shares Subject To Possible Redemption
InitialClassificationOfSharesSubjectToPossibleRedemption
237606630
sspk Deferred Underwriting Fee
DeferredUnderwritingFee
8750000
CY2019Q3 sspk Stock Conversion Percentage Threshold
StockConversionPercentageThreshold
0.2
sspk Limitation Period To Transfer Assign Or Sell Warrants
LimitationPeriodToTransferAssignOrSellWarrants
P30D
sspk Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
P60D
CY2019Q3 sspk Class Of Warrant Or Right Redemption Price Of Warrants Or Rights
ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
0.01
sspk Notice Period To Redeem Warrants
NoticePeriodToRedeemWarrants
P30D
sspk Period To File Registration Statement
PeriodToFileRegistrationStatement
P15D
sspk Period To Exercise Warrants After Business Combination
PeriodToExerciseWarrantsAfterBusinessCombination
P30D
sspk Period To Exercise Warrants After Public Offerings
PeriodToExerciseWarrantsAfterPublicOfferings
P12M
sspk Number Of Trading Days
NumberOfTradingDays
P20D
sspk Trading Days Threshold
TradingDaysThreshold
P30D
CY2019Q3 sspk Warrants Issued During Period Shares
WarrantsIssuedDuringPeriodShares
7000000
CY2019Q3 sspk Warrants Issued During Period Shares
WarrantsIssuedDuringPeriodShares
7000000
sspk Transaction Costs
TransactionCosts
14413362
sspk Other Offering Costs
OtherOfferingCosts
663362
CY2019Q3 sspk Redemption Price Per Share
RedemptionPricePerShare
10.00
CY2019Q3 sspk Interest Held To Pay Dissolution Expenses
InterestHeldToPayDissolutionExpenses
100000
CY2019Q3 sspk Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
25000000
sspk Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
25000000
CY2019Q3 sspk Warrants Issued During Period Price
WarrantsIssuedDuringPeriodPrice
1.00

Files In Submission

Name View Source Status
0001140361-19-020475-index-headers.html Edgar Link pending
0001140361-19-020475-index.html Edgar Link pending
0001140361-19-020475.txt Edgar Link pending
0001140361-19-020475-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sspk-20190930.xml Edgar Link completed
sspk-20190930.xsd Edgar Link pending
sspk-20190930_cal.xml Edgar Link unprocessable
sspk-20190930_def.xml Edgar Link unprocessable
sspk-20190930_lab.xml Edgar Link unprocessable
sspk-20190930_pre.xml Edgar Link unprocessable